Chinese life science solutions provider CapitalBio Technology has secured over 800 million yuan ($113 million) in financing ahead of a planned initial public offering (IPO) on the country’s Nasdaq-style STAR Market.
The investment will help CapitalBio “further consolidate a leading position in the genetic testing and biochip areas,” ahead of a planned shareholding restructuring and an application for an IPO on Shanghai’s STAR Market, said the company in a statement on late Thursday.
